Close

Gritgen Therapeutics Launches Commercial GMP Facility in China

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Gritgen Therapeutics Co., a biotechnology company focused on gene therapy products, reported the successful validation and launch of operations at its commercial GMP facility in Suzhou China for the production of Gritgen’s phase III clinical and commercial product for hemophilia A. The construction of Gritgen’s GMP facility adheres to the global cGMP standards and complies with the regulatory guidelines of authoritative agencies including the NMPA, the FDA and the EMA.

The 8,600 square meter facility covers plasmid production and AAV production lines. The production lines are based on a mature upstream process with mammalian cell suspension, and downstream process with chromatography platform technology, equipped with disposable bioreactors of different scales. The largest scale reaches 1,000 liters, taking into account of the productivity and quality of manufacturing.

It is equipped with pilot filling lines and commercial fill-finish lines to meet the need of drug product manufacture. The facility also has a quality control laboratory covering biochemical, physicochemical, molecular biological, and microbiological tests.

Wu Fenglan, Co-founder, and CEO of Gritgen, said, “The validation and operational launch of our GMP facility represents a pivotal juncture for Gritgen, which provides an important vector foundation for the company to realize commercialization. At the present, a bottleneck of gene therapy is the manufacturing process, a challenge resonating globally. The production capacity of large-scale, high-quality, cost controllable vectors is an important driving force for the development of gene therapy industry.”

Latest stories